company background image
PTN

Palatin TechnologiesNYSEAM:PTN Stock Report

Market Cap

US$97.6m

7D

1.0%

1Y

0.3%

Updated

19 Oct, 2021

Data

Company Financials +
PTN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PTN Overview

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Palatin Technologies
Historical stock prices
Current Share PriceUS$0.42
52 Week HighUS$0.38
52 Week LowUS$1.30
Beta1.21
1 Month Change-12.04%
3 Month Change-21.11%
1 Year Change0.33%
3 Year Change-54.38%
5 Year Change-17.22%
Change since IPO-99.99%

Recent News & Updates

Shareholder Returns

PTNUS BiotechsUS Market
7D1.0%1.7%4.0%
1Y0.3%15.6%30.5%

Return vs Industry: PTN underperformed the US Biotechs industry which returned 13.6% over the past year.

Return vs Market: PTN underperformed the US Market which returned 30% over the past year.

Price Volatility

Is PTN's price volatile compared to industry and market?
PTN volatility
PTN Beta1.21
Industry Beta0.98
Market Beta1

Stable Share Price: PTN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: PTN's weekly volatility has decreased from 13% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
198626Carl Spanahttps://palatin.com

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.

Palatin Technologies Fundamentals Summary

How do Palatin Technologies's earnings and revenue compare to its market cap?
PTN fundamental statistics
Market CapUS$97.64m
Earnings (TTM)-US$33.60m
Revenue (TTM)n/a

-521.2x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTN income statement (TTM)
Revenue-US$188.60k
Cost of RevenueUS$13.07m
Gross Profit-US$13.26m
ExpensesUS$20.33m
Earnings-US$33.60m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.15
Gross Margin7,032.45%
Net Profit Margin17,813.91%
Debt/Equity Ratio0%

How did PTN perform over the long term?

See historical performance and comparison

Valuation

Is Palatin Technologies undervalued compared to its fair value and its price relative to the market?

1.97x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PTN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PTN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PTN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PTN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PTN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PTN is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Palatin Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-1.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTN's revenue (35.8% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: PTN's revenue (35.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PTN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Palatin Technologies performed over the past 5 years?

16.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PTN is currently unprofitable.

Growing Profit Margin: PTN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTN is unprofitable, but has reduced losses over the past 5 years at a rate of 16.7% per year.

Accelerating Growth: Unable to compare PTN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: PTN has a negative Return on Equity (-67.66%), as it is currently unprofitable.


Financial Health

How is Palatin Technologies's financial position?


Financial Position Analysis

Short Term Liabilities: PTN's short term assets ($65.9M) exceed its short term liabilities ($10.5M).

Long Term Liabilities: PTN's short term assets ($65.9M) exceed its long term liabilities ($7.1M).


Debt to Equity History and Analysis

Debt Level: PTN is debt free.

Reducing Debt: PTN currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PTN has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 26.1% each year.


Dividend

What is Palatin Technologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PTN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.8yrs

Average management tenure


CEO

Carl Spana (59 yo)

21.33yrs

Tenure

US$2,292,617

Compensation

Dr. Carl Spana, Ph D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief...


CEO Compensation Analysis

Compensation vs Market: Carl's total compensation ($USD2.29M) is above average for companies of similar size in the US market ($USD545.22K).

Compensation vs Earnings: Carl's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PTN's management team is seasoned and experienced (10.8 years average tenure).


Board Members

Experienced Board: PTN's board of directors are seasoned and experienced ( 16.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Palatin Technologies, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Palatin Technologies, Inc.
  • Ticker: PTN
  • Exchange: NYSEAM
  • Founded: 1986
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$97.637m
  • Shares outstanding: 231.26m
  • Website: https://palatin.com

Number of Employees


Location

  • Palatin Technologies, Inc.
  • Cedar Brook Corporate Center
  • 4B Cedar Brook Drive
  • Cranbury
  • New Jersey
  • 8512
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/19 23:34
End of Day Share Price2021/10/19 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.